Haemonetics Corporation 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Haemonetics Corporation on March 3, 2026, regarding events occurring on March 2, 2026. The filing addresses the maturity and repayment of the Company's outstanding 0.00% Convertible Senior Notes due 2026.
Key Financial Metrics
- Debt Repayment: The Company repaid $300,000,000 in aggregate principal amount of the Convertible Senior Notes.
- Funding Source: Repayment was funded using cash on hand and borrowings under the Company's revolving credit facility.
- Conversion Activity: No holders exercised conversion rights prior to the maturity date.
- Derivatives: Capped call transactions associated with the Notes expired in accordance with their terms.
The filing does not provide specific values for revenue, profit, cash flow, margins, or overall liquidity positions beyond the specific transaction details.
Material Changes
The primary material change is the reduction of long-term debt obligations by $300,000,000 following the full repayment of the Notes at maturity. This transaction removed the specific liability from the balance sheet as of the maturity date.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks. The document strictly reports the execution of the debt repayment and the expiration of related capped call transactions.
Investor Verification Checklist
- Verify the impact of the $300,000,000 repayment on the Company's current cash balance and available liquidity.
- Confirm the amount of new borrowings drawn from the revolving credit facility to fund the repayment.
- Review the updated debt maturity schedule to reflect the removal of the 2026 Notes.
- Check subsequent filings for any changes in interest expense resulting from the shift from zero-coupon notes to revolving credit facility borrowings.